This CME program will highlight advanced treatment plans to improve outcomes for patients with primary biliary cholangitis (PBC). The expert faculty, led by Dr. Zobair Younossi, will first review the current science of PBC, including the burden of disease, testing and diagnostic strategies, the importance of early diagnosis, and current therapies for first line and second line treatment to slow disease progression. Next, an analysis of the clinical trial data for primary biliary cholangitis therapeutics, including dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonists, will be discussed. Following, the faculty will assess the treatment strategies to optimize the timing of second line therapies and how to address symptom management to improve outcomes for patients with PBC.
Hepatologists, gastroenterologists, nurses, APs and Pas
Review the current science of PBC, including the burden of disease, testing and diagnostic strategies, the importance of early diagnosis, and current therapies for first line and second line treatment to slow disease progression
Analyze clinical trial data for PBC therapeutics, including dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonists
Develop treatment strategies to optimize the timing of second line therapies and should identify and address symptom management to improve outcomes for patients with PBC
PBC Science, Diagnostic Strategies, Optimal Treatment Timing and Burden of Disease
Clinical Trial Data Review for PBC Therapeutics, Including Dual Peroxisome Activated Receptor (PPAR) Alpha/Delta Agonists
Treatment Strategies to Optimize Timing of Second Line Therapy and Identifying and Addressing Symptom Management to Improve Outcomes for Patients with PBC
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Zobair Younossi, MD | Consultant/Advisor: Abbott; Akero Therapeutics, Inc.; Bristol Myers Squibb; Boehringer Ingelheim International GmbH; Cymabay Therapeutics, Inc.; GSK plc.; Intercept Pharmaceuticals; Ipsen; Madrigal; Merck & Co., Inc.; Novo Nordisk; Siemens |
| Professor David Jones, OBE | Consultant/Advisor: Advanz Pharma; Cymabay Therapeutics, Inc./Gilead Sciences, Inc.; GSK; Intercept Pharmaceuticals; Ipsen; Umecrine Grant/Research Support: Intercept Pharmaceuticals Speaker’s Bureau: Ipsen; GSK |
| Andreas Kremer, MD, PhD | Consultant/Advisor: AbbVie Inc.; Advanz Pharma; Alentis Therapeutics AG; Alfasigma Global.; Avior Bio, Inc.; Bayer AG; Cymabay Therapeutics, Inc; Dr. Falk Pharma GmbH; Escient Pharmaceuticals; F. Hoffman-La Roche Ltd; Gilead Sciences, Inc.; GSK; Guidepoint Global, LLC.; Intercept Phaemaceuticals; Ipsen; Merck & Co., Inc.; Mirum Pharma; Novo Nordisk; Takeda Pharmaceutical Company Speaker: AbbVie Inc.; Advanz Pharma; AOP Orphan Pharmaceuticals GmbH; Bayer AG; Bristol Myers Squibb; Cymabay Therapeutics, Inc; Dr. Falk Pharma GbmH; Gilead Sciences. Inc.; F. Hoffman-La Roche Ltd; GSK; Intercept Pharmaceuticals; Ipsen; Merck & Co., Inc.; Mirum Pharma; NewBridge Pharmaceuticals; Novartis AG; Vertex Pharmaceuticals Incorporated; Viofor |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits TM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Ipsen.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Ipsen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
